Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...
Die Medikamente zur Gewichtsreduktion von Eli Lilly und Novo Nordisk sind in aller Munde. Dabei steht der nächste Blockbuster ...
Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk's weight-loss drug ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.